BRPI0920655A2 - conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos - Google Patents
conjugados e hpma-docetaxel ou gencitabina e usos dos mesmosInfo
- Publication number
- BRPI0920655A2 BRPI0920655A2 BRPI0920655A BRPI0920655A BRPI0920655A2 BR PI0920655 A2 BRPI0920655 A2 BR PI0920655A2 BR PI0920655 A BRPI0920655 A BR PI0920655A BR PI0920655 A BRPI0920655 A BR PI0920655A BR PI0920655 A2 BRPI0920655 A2 BR PI0920655A2
- Authority
- BR
- Brazil
- Prior art keywords
- docetaxel
- gemcitabine
- hpma
- conjugates
- water
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
compostos conjugados de hpma-docetaxel ou gencitabina e uso dos mesmos a presente invenção refere-se a cocomposições solúveis em água de gencitabina e docetaxel formadas conjugando-se a gencitabina ou docetaxel a um polímero solúvel em água tal como n-2-hidroxipropil metacrilamida (hpma). também são descritos métodos de usar as composições da invenção para o tratamento de câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10339008P | 2008-10-07 | 2008-10-07 | |
PCT/US2009/059869 WO2010042638A2 (en) | 2008-10-07 | 2009-10-07 | Hpma - docetaxel or gemcitabine conjugates and uses therefore |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0920655A2 true BRPI0920655A2 (pt) | 2019-07-09 |
Family
ID=41683287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0920655A BRPI0920655A2 (pt) | 2008-10-07 | 2009-10-07 | conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US9434610B2 (pt) |
EP (1) | EP2349347A2 (pt) |
JP (2) | JP2012505228A (pt) |
KR (1) | KR101705077B1 (pt) |
CN (2) | CN105879044A (pt) |
AU (1) | AU2009302387B2 (pt) |
BR (1) | BRPI0920655A2 (pt) |
CA (1) | CA2739757C (pt) |
IL (1) | IL212199A0 (pt) |
MX (1) | MX2011003738A (pt) |
WO (1) | WO2010042638A2 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
WO2004024776A1 (en) | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | Method of producing hydroxyalkyl starch derivatives |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
EP2336192A1 (en) | 2004-03-11 | 2011-06-22 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
EP2210616A1 (en) * | 2009-01-21 | 2010-07-28 | Centre National de la Recherche Scientifique | Multifunctional stealth nanoparticles for biomedical use |
EP2612857B1 (en) | 2010-05-27 | 2017-07-26 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate |
EP2590678A1 (en) * | 2010-07-09 | 2013-05-15 | Fresenius Kabi Deutschland GmbH | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
EP2919790B1 (en) | 2012-11-13 | 2018-04-04 | Boyen Therapeutics, Inc. | Gemcitabine prodrugs and uses thereof |
WO2016051752A1 (ja) * | 2014-09-29 | 2016-04-07 | 国立大学法人東北大学 | プロテアーゼの基質ペプチド及びプロテアーゼの活性測定方法 |
CA2976912A1 (en) * | 2015-02-17 | 2016-08-25 | Mallinckrodt Llc | Modified docetaxel liposome formulations and uses thereof |
CN106083960B (zh) * | 2016-06-15 | 2019-06-25 | 常州方圆制药有限公司 | 新型紫杉类化合物及其制备方法和应用 |
WO2018003739A1 (ja) * | 2016-06-30 | 2018-01-04 | レナセラピューティクス株式会社 | 機能的リガンドを含む核酸複合体 |
GB2551979A (en) * | 2016-06-30 | 2018-01-10 | Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd | Cleavable polymer drug conjugates |
CN106581690B (zh) * | 2016-12-23 | 2019-05-28 | 四川大学 | 肿瘤微环境刺激可降解的两亲性嵌段hpma聚合物给药系统及其制备方法 |
CN106880848B (zh) * | 2017-02-14 | 2019-09-06 | 四川大学 | 可生物降解的多聚HPMA-Gd磁共振成像探针及其制备方法 |
CN107550864B (zh) * | 2017-08-23 | 2020-12-18 | 科笛生物医药(上海)有限公司 | Eppt多肽-聚乙二醇-磷脂复合膜材料、其制备方法及主动靶向脂质体递药系统和应用 |
CN108359052B (zh) * | 2018-04-24 | 2020-11-17 | 辽宁大学 | 一种藤黄酸-叶酸-hpma高分子聚合物及其制备方法和应用 |
CN116262132A (zh) * | 2021-12-13 | 2023-06-16 | 深圳先进技术研究院 | 抗胰腺癌多肽药物偶联物及其无载体自组装纳米药物和制备方法及应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4074039A (en) | 1970-03-26 | 1978-02-14 | Ceskoslovenska Akademie Ved | Hydrophilic N,N-diethyl acrylamide copolymers |
CS159937B1 (pt) | 1972-02-29 | 1975-02-28 | ||
US3997660A (en) | 1972-02-29 | 1976-12-14 | Ceskoslovenska Akademie Ved | Soluble hydrophilic polymers and process for producing the same |
CS158458B1 (pt) | 1972-05-02 | 1974-11-25 | ||
CS173846B1 (pt) | 1974-04-23 | 1977-03-31 | ||
CS173849B1 (pt) | 1974-04-25 | 1977-03-31 | ||
GB8500209D0 (en) * | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
JP2001513078A (ja) | 1996-12-30 | 2001-08-28 | バテル・メモリアル・インスティテュート | 吸入により新生物を治療する製剤とその方法 |
US5965118A (en) * | 1997-04-18 | 1999-10-12 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6346349B1 (en) | 1999-02-11 | 2002-02-12 | Alcatel | Anode invention for lithium/transition metal fluoride molten salt cells and batteries |
US20010041189A1 (en) * | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
ES2223705T3 (es) | 1999-04-28 | 2005-03-01 | Board Of Regents, The University Of Texas System | Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf. |
AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
BRPI0014652B1 (pt) | 1999-10-12 | 2016-08-09 | Cell Therapeutics Inc | fabricação de conjugados de agente terapêutico-poliglutamato |
US7166733B2 (en) | 2000-01-04 | 2007-01-23 | Access Pharmaceuticals, Inc. | O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes |
AU2762101A (en) | 2000-01-04 | 2001-07-16 | Access Pharmaceuticals, Inc. | N,o-amidomalonate platinum complexes |
GB0018240D0 (en) * | 2000-07-25 | 2000-09-13 | Pharmacia & Upjohn Spa | Polymeric conjugates of antitumor agents |
CA2445985A1 (en) | 2001-05-04 | 2002-11-14 | University Of Utah Research Foundation | Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells |
AU2002357726A1 (en) * | 2001-11-15 | 2003-06-10 | The Regents Of The University Of California | Compositions and methods for the suppression of mammary epithelial cell proliferation |
WO2003066068A1 (en) | 2002-02-01 | 2003-08-14 | Intradigm Corporation | Hpma-polyamine conjugates and uses therefore |
WO2003101425A2 (en) | 2002-06-03 | 2003-12-11 | Alnis Biosciences, Inc. | Therapeutic agent-containing polymeric nanoarticles |
US20050129769A1 (en) | 2002-06-03 | 2005-06-16 | Barry Stephen E. | Polymeric articles for carrying therapeutic agents |
AU2003250391A1 (en) * | 2002-07-22 | 2004-02-09 | Psimei Pharmaceuticals Plc | Conjugates of biocompatible polymers with nuclide activation therapy reagents |
WO2004062588A2 (en) | 2003-01-06 | 2004-07-29 | University Of Utah | Water-soluble polymeric bone-targeting drug delivery system |
FR2858936A1 (fr) * | 2003-08-22 | 2005-02-25 | Diatos | Potentialisation de l'activation de prodrogues de haut poids moleculaire |
WO2005089106A2 (en) | 2004-02-27 | 2005-09-29 | Molecular Therapeutics, Inc. | Degradable nanoparticles |
US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
WO2006012355A2 (en) | 2004-06-28 | 2006-02-02 | University Of Maryland, Baltimore | Radiolabeled nanohybrids targeting solid tumor neovasculature and method of using same |
JP2008515915A (ja) | 2004-10-07 | 2008-05-15 | エモリー ユニバーシティー | 多機能性ナノ粒子結合体およびそれらの使用 |
WO2006113666A2 (en) | 2005-04-19 | 2006-10-26 | Massachusetts Institute Of Technology | Amphiphilic polymers and methods of use thereof |
US7647312B2 (en) * | 2005-05-12 | 2010-01-12 | Microsoft Corporation | System and method for automatic generation of suggested inline search terms |
DK1969031T3 (da) | 2005-12-05 | 2009-09-14 | Nitto Denko Corp | Polyglutamat-aminosyre-konjugater og fremgangsmåder |
CZ298945B6 (cs) * | 2006-09-18 | 2008-03-19 | Zentiva, A. S. | Polymerní lécivo a zpusob jeho výroby |
US8017141B2 (en) * | 2006-12-15 | 2011-09-13 | Advanced Cardiovascular Systems, Inc. | Coatings of acrylamide-based copolymers |
US8846110B2 (en) * | 2009-10-13 | 2014-09-30 | Rexahn Pharmaceuticals, Inc. | Polymeric systems for the delivery of anticancer drugs |
-
2009
- 2009-10-07 WO PCT/US2009/059869 patent/WO2010042638A2/en active Application Filing
- 2009-10-07 JP JP2011531149A patent/JP2012505228A/ja active Pending
- 2009-10-07 CA CA2739757A patent/CA2739757C/en not_active Expired - Fee Related
- 2009-10-07 US US12/575,276 patent/US9434610B2/en not_active Expired - Fee Related
- 2009-10-07 CN CN201610209937.9A patent/CN105879044A/zh active Pending
- 2009-10-07 EP EP09793342A patent/EP2349347A2/en not_active Withdrawn
- 2009-10-07 MX MX2011003738A patent/MX2011003738A/es active IP Right Grant
- 2009-10-07 CN CN2009801488749A patent/CN102264396A/zh active Pending
- 2009-10-07 AU AU2009302387A patent/AU2009302387B2/en not_active Ceased
- 2009-10-07 BR BRPI0920655A patent/BRPI0920655A2/pt not_active IP Right Cessation
- 2009-10-07 KR KR1020117010334A patent/KR101705077B1/ko active IP Right Grant
-
2011
- 2011-04-07 IL IL212199A patent/IL212199A0/en unknown
-
2014
- 2014-10-17 JP JP2014213125A patent/JP6013424B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN105879044A (zh) | 2016-08-24 |
JP2015034170A (ja) | 2015-02-19 |
KR101705077B1 (ko) | 2017-02-09 |
MX2011003738A (es) | 2011-09-30 |
JP6013424B2 (ja) | 2016-10-25 |
WO2010042638A2 (en) | 2010-04-15 |
CA2739757C (en) | 2016-07-05 |
AU2009302387A1 (en) | 2010-04-15 |
US9434610B2 (en) | 2016-09-06 |
CN102264396A (zh) | 2011-11-30 |
IL212199A0 (en) | 2011-06-30 |
AU2009302387B2 (en) | 2014-12-04 |
WO2010042638A3 (en) | 2010-05-27 |
JP2012505228A (ja) | 2012-03-01 |
CA2739757A1 (en) | 2010-04-15 |
KR20110076986A (ko) | 2011-07-06 |
EP2349347A2 (en) | 2011-08-03 |
US20100099644A1 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0920655A2 (pt) | conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos | |
CY1123470T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατοπαθειων | |
CY1120450T1 (el) | Διαμορφωτες υποδοχεων οιστρογονων και χρησεις εξ'αυτων | |
CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
BRPI0919447B8 (pt) | compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer | |
CY1121450T1 (el) | Θεραπεια συνδυασμου για θεραπεια καρκινου | |
BRPI0916286B8 (pt) | amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica | |
CY1118454T1 (el) | Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες | |
MX2010009670A (es) | Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer. | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
BR112015015319A2 (pt) | composições de nanopartícula de albumina e paclitaxel | |
CL2007001648A1 (es) | Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina. | |
ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
CL2012000302A1 (es) | Compuestos derivados de tubulisinas; compuestos conjugados que los comprenden; compuestos intermediarios; y uso para tratar el cancer. | |
UA118177C2 (uk) | Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну | |
BRPI0905733B8 (pt) | composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica | |
EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
CL2013003393A1 (es) | Inmunoconjugados (conjugados anticuerpo-fármaco) que en su estructura contienen un agente de unión al surco menor del adn (compuesto derivado de cbi), un grupo fosfato como grupo profármaco (protector) y un conector peptídico, útiles para el tratamiento de cáncer. | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
BR112012026801B8 (pt) | conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento | |
BR112013002220A2 (pt) | derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
EA200900571A1 (ru) | Композиции chk1 ингибиторов | |
ECSP099577A (es) | Formulaciones para el tratamiento del cáncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2599 DE 27/10/2020. |